Open AccessPB1916 MIRNAS AND ANGIOGENIC FACTORS IN PLASMA BEFORE AND AFTER TKI TREATMENT IN CML PATIENTS
Author(s) -
Litwińska Z.,
Łuczkowska K.,
Sobuś A.,
Rogińska D.,
PiusSadowska E.,
Paczkowska E.,
Gniot M.,
Lewandowski K.,
Helbig G.,
Machaliński B.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000566168.74492.74
Subject(s) - angiogenesis , angiogenin , medicine , microrna , myeloid leukemia , placental growth factor , endostatin , tyrosine kinase inhibitor , tyrosine kinase , cancer research , pathogenesis , thrombospondin 1 , vascular endothelial growth factor , immunology , pharmacology , biology , vegf receptors , cancer , gene , receptor , biochemistry
Background: The differences of an angiogenic potential between clinical phases of chronic myeloid leukemia (CML), point at the significance of neovascularisation in CML pathogenesis. Tyrosine kinase inhibitors (TKI), possessing antiangiogenic properties and microRNAs (miRNAs), implicated in governing angiogenesis, both seem vital in this process. Aims: In this study, we aimed to investigate how TKI treatment affects angiogenesis‐related miRNAs expression and angiogenic factors concentration in plasma of CML patients. Methods: Peripheral blood plasma samples were obtained from CML patients at the diagnosis (n = 23) and during TKI treatment (n = 12). Quantitative assessment of the expression of miRNA‐126‐3p, miRNA‐150‐5p and miRNA‐21‐3p was performed with qRT‐PCR. Concentrations of selected angiogenic factors in plasma (Angiogenin, bFGF, Endostatin,aFGF, PDGF‐AA, PIGF, Thrombospondin‐2, VEGF‐D, Angiopoietin‐1, VEGF) were assessed using multiplex fluorescent bead‐based immunoassays (Luminex Corporation). Results: MiRNA‐150‐5p and miRNA‐21‐3p expression was evidently higher in the treatment group (p = 0,001 and p = 0,03, respectively). PDGF‐AA concentration in newly diagnosed patients with CML was higher than in already treated patients (942,84 pg/ml vs 512,5 pg/ml, p = 0,02), similarly to VEGF (262,82 pg/ml vs 27 pg/ml, p = 0,03). Summary/Conclusion: TKI treatment affects miRNAs expression and angiogenic factors concentration in plasma of CML patients. MiRNAs could serve as biomarkers in monitoring CML progression and drug response, however, their exact role in CML‐related angiogenesis remains to be further elucidated.